SANDOSTATIN 200 MCG
OCTREOTIDE (OCTREOTIDE ACETATE) : 200 MCG · DIN 02049392 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is SANDOSTATIN?
SANDOSTATIN 200 MCG contains OCTREOTIDE (OCTREOTIDE ACETATE) : 200 MCG. It is listed in the Health Canada Drug Product Database under DIN 02049392, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for INTRAVENOUS ; SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 25-May-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOSTATIN used for?
SANDOSTATIN (octreotide acetate) therapy is indicated for control of symptoms in patients with metastatic carcinoid and vasoactive intestinal peptide-secreting tumours (VIPomas) as well as in patients with acromegaly. SANDOSTATIN is also indicated for the prevention of complications following pancreatic surgery in patients undergoing high-risk procedures. SANDOSTATIN is also indicated for the emergency management of bleeding gastro-oesophageal varices in patients with cirrhosis and as protection from re-bleeding. SANDOSTATIN LAR is indicated for acromegalic patients who are adequately controlled with SANDOSTATIN administered subcutaneously, including those in whom surgery, radiotherapy or dopamine agonist treatment is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. SANDOSTATIN LAR is indicated for the treatment of the severe diarrhoea and flushing episodes associated with carcinoid tumours in patients in whom symptoms are adequately controlled on subcutaneous treatment with SANDOSTATIN. SANDOSTATIN LAR is indicated for the treatment of the profuse watery diarrhoea associated with VIP-secreting tumours in patients in whom symptoms are adequately controlled on subcutaneous treatment with SANDOSTATIN.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02049392 |
|---|---|
| Brand name | SANDOSTATIN |
| Generic / active ingredient | OCTREOTIDE (OCTREOTIDE ACETATE) : 200 MCG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 200 MCG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | H01CB02 OCTREOTIDE |
| AHFS class | 92:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 25-May-2022 |
| Original market date | 1996-12-31 00:00:00 |
How is it stored and handled?
The SANDOSTATIN LAR kit must reach room temperature. Remove the kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. SANDOSTATIN diluted in physiological saline is stable for 24 hours when stored at room temperature. Discard unused portion.
How is it supplied?
SANDOSTATIN LAR 10 mg, 20 mg, 30 mg octreotide (as acetate) for injectable suspension
Is OCTREOTIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code H01CB02 OCTREOTIDE. 9 of 33 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OCTREOTIDE ACETATE OMEGA | 100 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02248640 |
| OCTREOTIDE ACETATE OMEGA | 200 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02248642 |
| OCTREOTIDE ACETATE OMEGA | 50 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02248639 |
| OCTREOTIDE ACETATE OMEGA | 500 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02248641 |
| OCTREOTIDE INJECTION | 100 MCG | SOLUTION | STERIMAX INC | MARKETED | DIN 02560240 |
| OCTREOTIDE INJECTION | 200 MCG | SOLUTION | STERIMAX INC | MARKETED | DIN 02560283 |
| OCTREOTIDE INJECTION | 500 MCG | SOLUTION | STERIMAX INC | MARKETED | DIN 02560291 |
| SANDOSTATIN | 50 MCG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 00839191 |
| SANDOSTATIN LAR | 30 MG | Powder For Suspension, Sustained-Release | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02239325 |
| OCPHYL | 100 MCG | SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02413205 |
Who else supplies OCTREOTIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OCTREOTIDE appears in 173 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.